Skip to main content

Table 1 Table

From: The incidence of serious bleeding events in a global, single-arm, open-label trial of Drotrecogin alfa (activated) in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS

  PROWESS: placebo PROWESS: DrotAA ENHANCE: DrotAA
Total n 840 850 2378
During infusion    
   Serious bleed 1.0 (n = 8) 2.4 (n = 20) 3.6 (n = 85)
   Fatal event 0.1 (n = 1) 0.5 (n = 4) 0.5 (n = 11)
Postinfusion    
   Serious bleed 1.1 (n = 9) 1.2 (n = 10) 2.9 (n = 70)
  1. Values are shown as rates (%) unless otherwise indicated.